An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called Ozari Health is now offering compounded versions of two popular weight-loss and diabetes drugs — semaglutide and tirzepatide — through a telehealth service across the U.S. They’re advertising prices starting around $86 per month for semaglutide and $125 per month for tirzepatide. The news also mentions updated 2026 pricing data for GLP-1 drugs going live, which is the background market context. Semaglutide and tirzepatide are drugs that mimic hormones your gut makes after you eat. Those hormones tell your brain you’re full and help control blood sugar. Semaglutide is the active ingredient in brand-name drugs like Ozempic and Wegovy. Tirzepatide is a newer drug that acts on two related hormone pathways. When a company “compounds” a drug, a pharmacy mixes up a version of it, rather than using a factory-made branded product. The story is not reporting a clinical trial or new health result. It’s about availability and price: Ozari’s telehealth platform will prescribe and ship compounded versions of these medicines nationwide at the listed starting prices. The update also notes fresh pricing data for GLP-1 class drugs in 2026. This is a market and access story — it doesn’t provide new evidence that the compounded versions work differently or are safer than brand-name products, and it doesn’t report how many people use it or long-term outcomes. Why this matters: GLP-1 drugs like semaglutide have become much more sought after for weight loss and diabetes control. Lower-cost compounded options could make them accessible to more people who can’t afford brand-name treatments or who face insurance barriers. Telehealth delivery can also be more convenient for busy people or those far from specialist clinics. Caveats and risks are important. Compounded drugs aren’t the same as FDA-approved brand products; they’re mixed by pharmacies and may not have the same testing for purity, dose consistency, or stability. The snippet doesn’t say whether Ozari’s compounded products have been independently tested or how they handle quality control. There are also medical risks: these medicines can have side effects and they aren’t safe for everyone. The story doesn’t report prescribing criteria, monitoring plans, or regulatory details, so anyone interested should check with a doctor and verify the pharmacy’s credentials before starting treatment. Bottom line: This is a pricing-and-access update — cheaper compounded semaglutide and tirzepatide are being offered through a telehealth service, which could broaden access, but quality, safety, and regulatory differences between compounded and brand drugs remain key questions.
Source: markets.businessinsider.com